![Stuart Naylor](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Stuart Naylor
Chief Tech/Sci/R&D Officer at
MEIRAGTX HOLDINGS PLC
Net worth: 9 M $ as of 2026-08-30
Profile
Stuart Naylor is Chief Development Officer at MeiraGTx Holdings Plc since 2019.
Formerly, Dr. Naylor was Chief Executive Officer at MeiraGTx UK II Ltd. from 2015 to 2016, Managing Director at Coltivare Ltd. from 2013 to 2015, and Chief Scientific Officer & Executive Director at Oxford Biomedica Plc from 2010 to 2013.
Education includes undergraduate studies at the University of Warwick and graduate studies at King's College London.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-07-06 | 640,846 ( 0.67% ) | 9 M $ | 2026-08-30 |
Stuart Naylor active positions
| Companies | Position | Start |
|---|---|---|
| MEIRAGTX HOLDINGS PLC | Chief Tech/Sci/R&D Officer | - |
Former positions of Stuart Naylor
| Companies | Position | End |
|---|---|---|
MeiraGTx UK II Ltd.
 MeiraGTx UK II Ltd. Pharmaceuticals: MajorHealth Technology Develops novel gene-based therapies for retinal disorders that lead to vision loss | Chief Executive Officer | 2016-03-31 |
Coltivare Ltd.
 Coltivare Ltd. Miscellaneous Commercial ServicesCommercial Services Provides management consulting services | Chief Executive Officer | 2015-03-31 |
| OXFORD BIOMEDICA PLC | Chief Tech/Sci/R&D Officer | 2013-06-05 |
Training of Stuart Naylor
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
35
1st degree connections
6
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Oxford Biomedica Plc
 Oxford Biomedica Plc BiotechnologyHealth Technology Operates as a contract development and manufacturing organization which provides viral vectors to pharmaceutical and biotechnology clients in cell and gene therapy fields | Health Technology |
University of Warwick
 University of Warwick Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
King's College London
 King's College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MeiraGTx Holdings Plc
 MeiraGTx Holdings Plc BiotechnologyHealth Technology Develops and manufactures genetic medicines | Health Technology |
MeiraGTx UK II Ltd.
MeiraGTx UK II Ltd. Pharmaceuticals: MajorHealth Technology Develops novel gene-based therapies for retinal disorders that lead to vision loss | Health Technology |
Coltivare Ltd.
Coltivare Ltd. Miscellaneous Commercial ServicesCommercial Services Provides management consulting services | Commercial Services |
- Stock Market
- Insiders
- Stuart Naylor
